Blog Big Molecule Watch January 24, 2018

Brazilian Society of Clinical Oncology Publishes Position Statement on Biosimilars in Oncology

This month the Brazilian Society of Clinical Oncology (SBOC) published a position paper on approval and use issues concerning biosimilars in oncology. The paper, published in the Brazilian Journal of Medical and Biological Research, discusses “aspects related to definition, labeling/nomenclature, extrapolation, interchangeability, switching, automatic substitution, clinical standards on safety and efficacy, and the potential impact on financial burden in healthcare.”  Overall, SBOC “take[s] a stand in favor of the introduction of biosimilars, as they offer a viable, safe, and cost-effective alternative to the biopharmaceutical products currently used in cancer.”

The post Brazilian Society of Clinical Oncology Publishes Position Statement on Biosimilars in Oncology appeared first on Goodwin Procter BioSimilars Blog.